Skip to content

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

BioWorld: Tolerogenic assets at heart of Cour-Genentech $940M autoimmune deal

By lsc-webmaster / December 3, 2024

Myasthenia Gravis News: First generalized MG patient dosed in immune-modifying therapy trial

COUR Pharmaceuticals Secures FDA Orphan Drug Designation for CNP-104 in Primary Biliary Cholangitis

Skokie, Illinois
info@courpharma.com

Science

Platform
Publications
Pipeline

Patients

Overview
Patient Resources
CNP-103 Clinical Trial in Type 1 Diabetes
CNP-106 Clinical Trial in Myasthenia Gravis

Company

About Us
Partnerships
News
Careers

Privacy Policy
Terms of use
Accessibility
Expanded Access Policy
Cookie policy

© 2025 COUR Pharmaceuticals

Scroll to Top